Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial.

von Bardeleben, Ralph Stephan; Lurz, Philipp; Sorajja, Paul; Ruf, Tobias; Hausleiter, Jörg; Sitges, Marta; Da Rocha E Silva, Jaqueline; Näbauer, Michael; Weber, Marcel; Tang, Gilbert H L; Heitkemper, Megan; Ying, Shih-Wa; Trochu, Jean-Noel; Kar, Saibal; Hahn, Rebecca T; Nickenig, Georg (2023). Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial. Circulation. Cardiovascular interventions, 16(8), e012888. American Heart Association 10.1161/CIRCINTERVENTIONS.122.012888

Text Two-Year_Outcomes_for_Tricuspid_Repair_With_a_Transcatheter_Edge-to-Edge_Valve_Repair_From_the_Transatlantic_TRILUMINATE_Trial.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (862kB) | Request a copy

BACKGROUND

Tricuspid regurgitation (TR) is a common and progressive valve disease with significant mortality and hospitalization burden. Tricuspid transcatheter edge-to-edge repair provides a treatment option for high-risk patients with primary and secondary TR.

METHODS

The TRILUMINATE trial ([Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation]; n=85) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of tricuspid transcatheter edge-to-edge repair with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessment was performed at a core laboratory. Outcomes included safety and clinical effectiveness and echocardiographic assessment of TR.

RESULTS

At 2 years, TR was reduced to moderate or less in 60% of subjects, and reduction of at least 1 grade was achieved in 85.4% of subjects. TR reduction was sustained in 75% of the patients. While most metrics suggest the majority of favorable remodeling occurred within the first 30 days post-procedure, both right ventricular end diastolic diameter and tricuspid annular plane systolic excursion show signals of continued favorable remodeling through 2 years. Substantial improvements in 6-minute walking distance, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire score were sustained from 30 days to 2 years. Even with low rates of cardiovascular mortality (15.3%) and all-cause mortality (18.7%) noted at 2 years, all-cause hospitalization rate decreased from 1.30 events per patient-year 1 year before device implantation to 0.66 events per patient-year 2 years after the TriClip procedure, representing a reduction of 49% (P<0.0001).

CONCLUSIONS

Tricuspid transcatheter edge-to-edge repair using the TriClip implant was found to be safe and effective, with sustained benefits at 2 years in subjects with symptomatic moderate or greater TR. Repair efficacy was durable at 2 years in 75% of the patients.

REGISTRATION

URL: https://www.

CLINICALTRIALS

gov; Unique identifier: NCT03227757.

Interest & Impact

Downloads

0 since deposited on 28 Dec 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item